Faculty

Qizhou LIAN

Distinguished Professor
  • Department of Engineering Biology
  • E-mail:

    lianqizhou@suat-sz.edu.cn

Qizhou Lian is a Distinguished Professor under the National Major Talent Program at Shenzhen University of Advanced Technology (SUAT) and an adjunct Principal Investigator at the Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences. He has over 20 years of experience in clinical practice, scientific research, and translational medicine, specializing in cell and gene therapy as well as GMP biomanufacturing. In 2014, he completed Asia's first hematopoietic stem cell gene therapy for metachromatic leukodystrophy (MLD) and is leading Asia's only cohort with over 10 years of follow-up. In 2024, he led a cross-border medical rescue for a Swedish child with MLD, successfully halting disease progression and enabling the patient to return to school. He has established a comprehensive GMP manufacturing standard for mesenchymal stromal cells (MSCs) derived from pluripotent stem cells and created the first international GMP cell therapy manufacturing center at the University of Hong Kong. He also serves as the technical lead for multiple cell therapy projects at the SUAT General Hospital. Prof. Lian is an Associate Editor of the international medical journal Transplantation (JCR Q1 in Surgery). He serves as a grant review expert for over ten national and regional scientific funding agencies, including the French National Research Agency (ANR), Israel Science Foundation (ISF), UK Research and Innovation (UKRI), National Natural Science Foundation of China (NSFC), and the Hong Kong Science and Technology Parks (HKSTP) IncuBio Entrepreneurship Fund.

Research Areas

Stem Cells:Directed differentiation of pluripotent stem cells into therapeutically useful cells and tissues; establishing clinical-grade Mesenchymal stromal cells (MSCs) from pluripotent sources; utilizing synthetic biology to enhance the immunomodulatory functions of MSCs.

Cell and Gene Therapy:Developing innovative technologies for hematopoietic stem cell gene therapy (e.g., for MLD); clinical translation and GMP manufacturing.

Synthetic Biology & Enabling Technology:Integrating synthetic biology strategies with AI-assisted methods to develop novelin vivo approaches for delivering mRNA, proteins, and CAR-T therapeutics.

Education and Professional Experience

He received his early undergraduate and postgraduate education in the integration of Western and Chinese medicine from Fujian University of Traditional Chinese Medicine. He earned his Doctor of Medicine (M.D.) and Ph.D. degrees in 1999 from Harbin Medical University. After completing fellowship training in Cardiology, he also conducted postdoctoral research in stem cell and developmental biology at the Singapore Genomic Institute and Utrecht Medical Centre in the Netherlands. He started his independent career as an Assistant Professor at The University of Hong Kong in 2010.

Academic Achievements

1.Established clinically compliant mesenchymal stromal cells (MSCs) derived from human pluripotent stem cells and explored their applications (Stem Cells 2008; Circulation 2011, etc.).

2.Led Asia’s first hematopoietic stem cell gene therapy for symptoms of metachromatic leukodystrophy, resulting in long-term recovery (Protein & Cell 2024; Molecular Therapy Nucleic Acids 2025; Molecular Therapy-Methods & Clinical Development 2025).

3. Established the first Cell Therapy GMP manufacturing facilities at HKU (Medicinal Research Review 2024).

4. Developed synthetic biology enabling technology to construct engineered immune cells with diverse regulatory modules. ie.,Aux-CART (Adv Sci 2026)

Awards:

·Global Top 2% Scientists List ( Sandford &Elsevier 2026)

·Excellent Professoriate Award, Shenzhen University of Advanced Technology, 2025

·Outstanding Research Contribution Award, Shenzhen University of Advanced Technology, 2024

·Excellent Research Award, LKS Faculty of Medicine, The University of Hong Kong, 2024

·10th ISSCR Travel Grant Award, International Society of Stem Cell Research, Yokohama, Japan, 2012

·Young Scientist Award, 2nd International Symposium of Healthy Ageing, Hong Kong, 2007

·Young Scientist Scholarship Award, the 10th Annual Symposium of the Society of Chinese

·Bio-scientists in America (SCBA), USA, 2004

Major Research Projects, Representative Publications

Projects

1.2023-2028: National Key R&D Program: Spatiotemporal Intervention Techniques for Tumor Cell Death by using Synthetic Biology Strategies (In progress).

2.2022-2027: National Key R&D Program: Role of Stem Cells in the Pathogenesis and Damage Repair Mechanisms of Respiratory System Exposed to COVID-19 (In progress).

3.2025-2027: Shenzhen-Hong Kong Joint Funding Program (Type A): Study on Postoperative Hepatic Injury Repair via Pluripotent Stem Cell Therapy and Mitochondrial Function Restoration (In progress).

Representative Publications

(>200 peer-reviewed papers in journals including Circulation, Cell Stem Cell, Nature Metabolism, Nature Communications, etc.). To view the full publication list of Prof. Lian, please visit:

PubMed:https://pubmed.ncbi.nlm.nih.gov/?term=Lian+Qizhou&sort=date

Google Scholar:https://scholar.google.com/citations?user=I1j8ZWcAAAAJ&hl=en

Representative Papers(* Corresponding / Co-Corresponding Author)

1.Su Q, Long Y, Duan F, Lian Q.scBOA: Bayesian optimization of single-cell analysis pipelines for robust annotation and discovery.Nature Communications (in press), 2026.

2.Chen L, Zhai X, Chen S, et al., Lian Q.ITLN1 suppresses colorectal cancer progression by orchestrating neutrophil maturation and spatial organization.Nature Communications (in press), 2026.

3.Zeng H, Zheng L, Tao R, et al., Lian Q.Repurposing a small molecule plant hormone as a tunable ON-switch for CAR-T cell immunotherapy.Advanced Science,August 21e77020, 2026.

4.Zhang Z, Jiang H, Huang L, et al., Lian Q.Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study.Protein Cell, 16(1): 16–27, 2025.

5.Ma CY, Zhai Y, Li CT, Liu J, Tse HF, Lian Q. Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: promises, problems and prospects.Medicinal Research Reviews, 44(3): 919–838, 2024.

6.Lian Q*, Zhang K, Zhang Z, et al., Chen HJ*. Differential effects of macrophage subtypes on SARS-CoV-2 infection in a human pluripotent stem cell-derived model.Nature Communications, 13(1): 2028, 2022.

7.Geng L, Liao B, Jin L, et al., Lian Q*, Xu A*. β-Klotho promotes glycolysis and glucose-stimulated insulin secretion via GP130.Nature Metabolism, 4(5): 608–626, 2022.

8.Jin L, Geng L, Ying L, et al., Lian Q*, Xu A*. FGF21–Sirtuin 3 axis confers the protective effects of exercise against diabetic cardiomyopathy by governing mitochondrial integrity.Circulation,146(20): 1537–1557, 2022.

9.Zhang Z, Yan B,et al., Lian Q. Pluripotent Stem Cells Reveal Poly-unsaturated Fatty Acids-provoked Mitochondrial Stress as a Central Node Potentiating Retinal Pigmented Epithelium Degeneration in Bietti’s Crystalline Dystrophy .Molecular Therapy 2020 Jul 25;S1525-0016(20)30375-0

10.Lian Q*, Zhang Y,et al.,Tse HF*. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice.Circulation.2010 Mar 9;121(9):1113-20

职称 Distinguished Professor 系别 Department of Engineering Biology
邮箱 lianqizhou@suat-sz.edu.cn 职称2